NCT05058040 · Phase 4 · ACTIVE NOT RECRUITING
A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971)
This study tracks the long-term safety of sodium oligomannate capsules (GV-971), a drug taken by people with Alzheimer's disease. It follows patients whose own doctors have already prescribed it, watching for side effects over time. It is a Phase 4 trial, meaning it looks at safety after a drug is already in use, not whether it works. Details are limited so far.
Eligibility criteria
Inclusion Criteria: * Subjects eligible for this study must meet all of the following criteria: 1. ≥18 years of age; 2. Signed informed consent form; 3. Patients receiving GV-971 treatment prescribed by clinicians; Exclusion Criteria: * A subject may be excluded from participation in the study if any of the following apply: 1. Patients who may be allergic to Sodium Oligomannate Capsules as judged by the investigator; 2. Female participants who are pregnant or lactating; 3. Patients who cannot cooperate to complete the follow-up inquiries; 4. Any other diseases or conditions that are inappropriate to participate in this clinical trial in the opinion of the investigator.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-01-24